A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
2022-06-28
عنوان الدراسة
A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
داعم الدراسة
Novartis
دواء الدراسة
Pasireotide
رقم بروتوكول الدراسة
CSOM230C2402
حالة الدراسة
Ongoing
موقع الدراسة
NGHA-R
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。